SAN DIEGO, July 20, 2026
Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase 3 DRAGON trial evaluating tinlarebant for the treatment of Stargardt disease type 1 (STGD1) during an oral presentation at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting in Montréal, Canada. The company reported that tinlarebant, the first investigational therapy to demonstrate clinical efficacy in STGD1, continued to show encouraging clinical benefit following previously announced positive topline results. The presentation highlighted significant findings from quantitative autofluorescence (qAF) analyses, demonstrating that patients treated with tinlarebant maintained stable or slightly reduced qAF values after 25 months, while placebo-treated patients experienced an approximately 20% increase, reflecting continued accumulation of toxic retinal bisretinoids. Belite Bio also confirmed that its New Drug Application (NDA) for tinlarebant has been completed and submitted to the U.S. Food and Drug Administration (FDA) for regulatory review.
Phase 3 DRAGON Trial Demonstrates Durable Clinical Benefit
The global Phase 3 DRAGON trial enrolled 104 patients across 11 countries, randomizing participants in a 2:1 ratio to receive tinlarebant or placebo. Previously reported topline results showed that the study successfully met its primary efficacy endpoint, demonstrating a 35.7% statistically significant reduction in retinal lesion growth, measured by definitely decreased autofluorescence (DDAF) on retinal imaging compared with placebo. During the ASRS presentation, investigators expanded upon these findings by presenting supportive secondary endpoint data, including quantitative autofluorescence (qAF), a biomarker reflecting toxic bisretinoid accumulation associated with Stargardt disease progression. Patients receiving tinlarebant maintained stable retinal autofluorescence levels over 25 months, whereas placebo-treated patients experienced marked disease progression, further supporting the drug’s disease-modifying potential. Tinlarebant was also reported to be well tolerated throughout the Phase 3 study, reinforcing its favorable safety profile.
Tinlarebant Targets the Underlying Cause of Stargardt Disease
Tinlarebant (LBS-008) is a novel oral therapy designed to reduce the accumulation of vitamin A-derived bisretinoid toxins, which are responsible for progressive retinal degeneration in Stargardt disease type 1 and also contribute to geographic atrophy (GA) associated with advanced dry age-related macular degeneration. The therapy works by lowering circulating levels of retinol-binding protein 4 (RBP4), the primary transporter responsible for delivering vitamin A from the liver to the retina. By reducing retinal vitamin A availability, tinlarebant decreases formation of toxic bisretinoids that damage retinal cells. The investigational therapy has received multiple regulatory incentives, including Breakthrough Therapy Designation, Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation in multiple global markets, highlighting its potential to address the significant unmet medical need for patients with inherited retinal diseases.
Advertisement
Regulatory Review Advances as Belite Bio Expands Retinal Pipeline
The completion of the FDA New Drug Application marks a major milestone for Belite Bio as the company advances what could become the first approved treatment for Stargardt disease type 1. In addition to the completed Phase 3 DRAGON trial, tinlarebant continues to be evaluated in the Phase 2/3 DRAGON II trial for adolescents and adults with STGD1 and the Phase 3 PHOENIX trial for geographic atrophy (GA) secondary to advanced dry age-related macular degeneration. By targeting the underlying disease mechanism rather than only managing symptoms, tinlarebant has the potential to transform treatment for inherited retinal disorders. The latest ASRS data further strengthen the clinical evidence supporting the therapy as Belite Bio progresses through the FDA review process and prepares for potential commercialization.
Source: Belite Bio press release
